attr()

0:17:04

Understanding Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Rare Heart Disease

0:04:11

What key challenges remain in the diagnosis of ATTR amyloidosis?

0:06:59

Prise en charge et suivi des patients ATTR-CM*

0:05:54

Diagnostic différentiel : Amylose à transthyrétine (ATTR) / Amylose à chaîne légère (AL)

0:00:50

The impact of acoramidis on clinical outcomes in ATTR-CM

0:07:11

Collaboration Cardiologue & Hématologue interniste dans l'amylose ATTR

0:15:14

ATTR: What Treatments are in our Future

0:03:24

ESC HF 25: CRISPR in ATTR-CM: Hereditary vs Wild-Type

0:08:45

ATTR Amyloidosis - Behind The Mystery

0:01:26

CSS Attribute [attr] Selector

0:02:38

How to Use the ATTR Function in Tableau & Two Use Cases

0:01:01

Living with ATTR: Symptoms and Diagnosis

0:01:00

The attr CSS Function Is Incredible

0:00:31

Alnylam’s Amvuttra Scores FDA Nod as First RNAi Drug in ATTR-CM, Set to Take on Pfizer’s Vyndaqel

0:13:28

Expert Insights Into Amyloidosis: Diagnosing AL and ATTR Cardiac Amyloidosis

1:45:40

What's new and exciting in ATTR cardiac amyloidosis in 2024

2:20:47

ASG ATTR Webinar, January 21, 2023

0:00:27

Hereditary ATTR-CM

0:03:53

Recognizing Early Indicators of ATTR-CM

0:04:39

CSS attr( ) method

0:15:57

ATTR: Molecules That Cause and Molecules That Treat TTR Amyloidosis

0:04:14

A Detailed Overview of ATTR Cardiomyopathy

2:05:57

Treatments for Transthyretin Amyloidosis (ATTR)

0:03:17

Monitoring ATTR-CM Progression